GMDA · Gamida Cell Ltd

-

Please sign in to comment on GMDA

1 Comment

Admin

4 years, 1 month ago

Gamida Cell Ltd is currently in a long term downtrend where the price is trading 19.4% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Gamida Cell Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 119.5% to $-32M since the same quarter in the previous year.

Finally, its free cash flow fell by 27.3% to $-16M since the same quarter in the previous year.

Based on the above factors, Gamida Cell Ltd gets an overall score of 1/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	IL0011552663
Sector	Healthcare
Industry	Biotechnology

Market Cap	4M
PE Ratio	None
Target Price	4
Beta	1.03
Dividend Yield	None

ABOUT

Gamida Cell Ltd

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

GMDA · Gamida Cell Ltd

-

Gamida Cell Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Gamida Cell Ltd using a moving average strategy